Saturday 17 October 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

In the quarter to June 2026, EPS fell 61.5% and free cash flow fell 92.6%, each against the same quarter a year earlier.

63.62 1.65 −2.53%

Follow PCVX

Alert me

Market cap: $10.3B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 12.32

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	—	2	2	1	4	3	3	2	3

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 10,270.00

Revenue —

Net Income (1,064.26)

Free Cash Flow (894.14)

Net Debt (1,486.84)

Current Ratio 5.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.33

Past 5Y EPS Growth —

This Y EPS Growth (46.38%)

Next Y EPS Growth 21.64%

Next Y revenue growth —

Next 5Y EPS Growth (2.23%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 47.44%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,080	1,747	1,561	1,487
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,096	1,788	1,627	1,553

	2023	2024	2025	Q'26
Payables	15	48	71	101
ST’ Debt	—	—	—	—
Other	—	—	—	—
	145	140	206	271

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	50.67%	41.22%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(281)	(232)	—	—	—
’25	(166)	(121)	(143)	(225)	(656)
’24	(159)	(121)	(61)	(111)	(453)
’23	(48)	(63)	(58)	(129)	(297)
’22	(28)	(39)	(39)	(65)	(171)
’21	(13)	(29)	(28)	(51)	(121)
’20	(14)	(9)	(13)	(11)	(47)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(283)	(237)	—	—	—
’25	(172)	(123)	(147)	(227)	(669)
’24	(165)	(129)	(66)	(115)	(475)
’23	(53)	(61)	(65)	(134)	(313)
’22	(31)	(40)	(39)	(66)	(176)
’21	(14)	(31)	(30)	(52)	(128)
’20	(14)	(9)	(13)	(11)	(48)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.30)	(1.97)	—	—	—
’25	(1.04)	(1.22)	(1.56)	(1.80)	(5.63)
’24	(0.85)	(1.10)	(0.83)	(1.02)	(3.80)
’23	(0.70)	(0.70)	(0.91)	(1.82)	(4.14)
’22	(0.68)	(0.80)	(0.93)	(1.03)	(3.44)
’21	(0.41)	(0.46)	(0.51)	(0.54)	(1.93)
’20	(6.70)	(1.72)	(0.41)	(0.41)	(3.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	17.80	15.51	16.78	34.11	53.83	27.66	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	58.48	30.88	48.19	64.04	121.06	93.77
People
People	Employees	—	—	—	43	58	89	158	254	414	507
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(29)	(50)	(89)	(100)	(223)	(402)	(464)	(767)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(29)	(50)	(89)	(100)	(223)	(402)	(464)	(767)
	Depreciation	—	—	1	1	1	5	9	(25)	(23)	10
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(8.12)	(13.25)	(3.02)	(1.93)	(3.44)	(4.14)	(3.80)	(5.63)
	Cash flow	—	—	(8.39)	(12.42)	(1.58)	(2.34)	(2.63)	(3.05)	(3.71)	(4.82)
	Capex	—	—	(0.49)	(0.31)	(0.04)	(0.13)	(0.09)	(0.17)	(0.18)	(0.10)
	Free cash flow	—	—	(8.88)	(12.74)	(1.62)	(2.46)	(2.72)	(3.22)	(3.89)	(4.92)
	Book value	—	—	16.55	14.21	11.71	5.47	14.70	12.77	27.10	19.73
	Shares, m	—	—	4	4	30	52	65	97	122	136
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(30)	(47)	(47)	(121)	(171)	(297)	(453)	(656)
	Capex	—	—	(2)	(1)	(1)	(7)	(6)	(16)	(22)	(14)
	Free cash flow	—	—	(32)	(48)	(48)	(128)	(176)	(313)	(475)	(669)
Balance, $m
Balance, $m	Working capital	—	—	60	51	342	228	902	951	1,648	1,422
	Total debt	—	—	0	0	—	17	18	—	—	—
	Net debt	—	—	(66)	(59)	(386)	(246)	(931)	(1,080)	(1,747)	(1,561)
	Shareholders’ equity	—	—	60	54	346	284	954	1,240	3,306	2,686
Returns, %
Returns, %	ROA	—	—	(83.29)	(73.66)	(38.91)	(27.91)	(33.59)	(33.33)	(18.86)	(23.54)
	ROIC	—	—	0.00	0.00	0.00	(170.29)	(652.79)	(182.55)	(22.84)	(51.34)
	ROE	—	—	35.94	61.27	(74.51)	(31.78)	(36.11)	(36.67)	(20.41)	(25.59)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)	Compare
Median of peers	$10.2B	71.6×	38.1×	+34.76%	—	+9.22%	84.74%	(2.62%)

All 614 Biotechnology stocks →

Vaxcyte, Inc. (PCVX) key facts

Concern: Vaxcyte, Inc. reported a net loss of $766.6 million, or a loss of $5.63 per share, for fiscal 2025.
Vaxcyte, Inc. (PCVX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PCVX traded at $63.62, a market capitalization of $10.3 billion.
Return on equity was −25.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.